Advances in the treatment of acne

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 53, Issue 9 SUPPL., 2008, Pages 742-752

  Kimball, Alexa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acne vulgaris; Drospirenone; Oral contraceptives, combined; YAZ

Indexed keywords

ADAPALENE; AMPICILLIN; ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ERYTHROMYCIN; ESTROGEN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; ISOTRETINOIN; MINOCYCLINE; NANDROLONE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RETINOIC ACID; RETINOID; SALICYLIC ACID; SPIRONOLACTONE; STEROID; SULFACETAMIDE; TAZAROTENE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YAZ; ZINC;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; BACKACHE; BLEEDING; BLOATING; BLOOD DISEASE; BONE DISEASE; BRADYCARDIA; BRAIN PSEUDOTUMOR; BREAST TENDERNESS; CLINICAL FEATURE; CLINICAL TRIAL; COMEDO; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRY EYE; DRY LIPS; DRY SKIN; DYSPHAGIA; EPISTAXIS; ERYTHEMA; ESOPHAGEAL IRRITATION; ESOPHAGUS DISEASE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HORMONAL THERAPY; HUMAN; HYPERKALEMIA; HYPEROSTOSIS; HYPERSENSITIVITY REACTION; HYPERTROPHIC SCAR; INFLAMMATION; KELOID; LIP DISEASE; LIPID BLOOD LEVEL; LIVER INJURY; LIVER TOXICITY; MENSTRUAL IRREGULARITY; METRORRHAGIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NIGHT VISION; PANCREATITIS; PAPANICOLAOU TEST; PATHOGENESIS; PATIENT COUNSELING; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOSENSITIZATION; PIGMENTATION; PREVALENCE; PRIORITY JOURNAL; PROPIONIBACTERIUM; QUALITY OF LIFE; REVIEW; SCAR FORMATION; SEBACEOUS GLAND; SEBUM SECRETION; SIDE EFFECT; SINUSITIS; SKIN ABRASION; SKIN BURNING SENSATION; SKIN DISCOMFORT; SKIN DISEASE; SKIN IRRITATION; SKIN PRURITUS; SKIN SCALING; SKIN SENSITIZATION; SKIN SORENESS; SKIN STINGING SENSATION; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; WEIGHT GAIN;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROSTENES; ANTI-INFECTIVE AGENTS, LOCAL; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; HUMANS; TRETINOIN;

EID: 53649084057     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. YAZ® drospirenone and ethinyl estradiol tablets. Prescribing information. Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey, 2007. Available at: http.//berlex.bayer-healthcare.com/html/products/pi/fhc/YAZ_PI. pdf. Accessed April 2008
2. Layton AM: A review on the treatment of acne vulgaris. Int J Clin Pract 2006;60:64-72
3. Purdy S, de Berker D: Acne. Br Med J 2006;333:949-953
4. O'Connell K, Westhoff C: Pharmacology of hormonal contraceptives and acne. Cutis 2008;81:8-12
5. Clarke SB, Nelson AM, George RE, et al: Pharmacologic modulation of sebaceous gland activity: Mechanisms and clinical applications. Dermatol Clin 2007;25:137-146
6. James WD: Clinical practice: Acne. N Engl J Med 2005;352:1463-1472
7. Dreno B: Acne: Physical treatment. Clin Dermatol 2004;22:429-433
8. Haider A, Shaw JC: Treatment of acne vulgaris. J Am Med Assoc 2004;292:726-735
9. Ballanger F, Baudry P, N'Guyen JM, et al: Heredity: A prognostic factor for acne. Dermatology 2006;212:145-149
10. Grumbach MM, Styne DM: Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In Williams Textbook of Endocrinology. Tenth edition. Edited by PR Larsen, HM Kronenberg, S Melmed, et al. Philadelphia, Saunders, 2003, pp 1115-1286
11. Slayden SM, Moran C, Sams WM Jr, et al: Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001;75:889-892
12. Centers for Disease Control and Prevention: Prevalence of overweight among children and adolescents: United States, 1999-2002. Available at: www.cdc.gov/nchs/products/pubs/pubd/hestats/overwght99.htm. Accessed April 2008
13. McCartney CR, Blank SK, Prendergast KA, et al: Obesity and sex steroid changes across puberty: Evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 2007;92:430-436
14. Tsai MC, Chen W, Cheng YW, et al: Higher body mass index is a significant risk factor for acne formation in schoolchildren. Eur J Dermatol 2006;16:251-253
15. Danby FW: Diet and acne. Clin Dermatol 2008;26:93-96
16. Adebamowo CA, Spiegelman D, Danby FW, et al: High school dietary dairy intake and teenage acne. J Am Acad Dermatol 2005;52:207-214
17. Kaymak Y, Adisen E, Ilter N, et al: Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne. J Am Acad Dermatol 2007;57:819-823
18. Chiu A, Chon SY, Kimball AB: The response of skin disease to stress: Changes in the severity of acne vulgaris as affected by examination stress. Arch Dermatol 2003;139:897-900
19. Yosipovitch G, Tang M, Dawn AG, et al: Study of psychological stress, sebum production and acne vulgaris in adolescents. Acta Derm Venereol 2007;87:135-139
20. White GM: Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998;39:S34-S37
21. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). What is acne? Available at: www.niams.nih.gov/Health_Info/Acne/acne_ff. pdf. Accessed April 2008
22. Thiboutot D, Dreno B, Layton A: Acne counseling to improve adherence. Cutis 2008;81:81-86
23. Kilkenny M, Merlin K, Plunkett A, et al: The prevalence of common skin conditions in Australian school students: III. Acne vulgaris. Br J Dermatol 1998;139:840-845
24. Lello J, Pearl A, Arroll B, et al: Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J 1995;108:287-289
25. Collier CN, Harper JC, Cantrell WC, et al: The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008;58:56-59
26. Goulden V, Stagles GI, Cunliffe WJ: Prevalence of facial acne in adults. J Am Acad Dermatol 1999;41:577-580
27. Fried RG, Wechsler A: Psychological problems in the acne patient. Dermatol Ther 2006;19:237-240
28. Thiboutot DM: Overview of acne vulgaris and its treatment. Cutis 2008;81:3-7
29. Thomas DR: Psychosocial effects of acne. J Cutan Med Surg 2005;8:3-5
30. American Academy of Dermatology: The social impact of acne. Available at: www.skincarephysicians.com/acnenet/socimpct.html. Accessed April 2008
31. Tan JK: Psychosocial impact of acne vulgaris: Evaluating the evidence. Skin Therapy Lett 2004;9:1-3, 9
32. Bowe WP, Leyden JJ, Crerand CE, et al: Body dysmorphic disorder symptoms among patients with acne vulgaris. J Am Acad Dermatol 2007;57:222-230
33. Gupta MA, Gupta AK: Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-850
34. Nijsten T, Rombouts S, Lambert J: Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. J Eur Acad Dermatol Venereol 2007;21:163-168
35. Pawin H, Chivot M, Beylot C, et al: Living with acne: A study of adolescents' personal experiences. Dermatology 2007;215:308-314
36. Yan AC: Current concepts in acne management. Adolesc Med Clin 2006;17:613-637
37. Thiboutot D: New treatments and therapeutic strategies for acne. Arch Fam Med 2000;9:179-187
38. Katsambas AD, Stefanaki C, Cunliffe WJ: Guidelines for treating acne. Clin Dermatol 2004;22:439-444
39. Strauss JS, Krowchuk DP, Leyden JJ, et al: Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-663
40. Akhavan A, Bershad S: Topical acne drugs: Review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003;4:473-492
41. Tanghetti E: The impact and importance of resistance. Cutis (suppl 1) 2007;80:5-9
42. Thiboutot D: Hormones and acne: Pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg 2001;20:144-153
43. Rich P: Hormonal contraceptives for acne management. Cutis 2008;81:13-18
44. Mishell DR Jr: Family planning. In Comprehensive Gynecology. Fifth edition. Edited by VL Katz, RA Lobo, GM Lentz, et al. St Louis, Mosby, 2007, pp 275-325
45. Harper JC: Hormonal therapy for acne using oral contraceptive pills. Semin Cutan Med Surg 2005;24:103-106
46. Krattenmacher R: Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38
47. Dinger JC, Heinemann LA, Kuhl-Habich D: The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-354
48. Loughlin J, Seeger J, Eng PMJ, et al: Health outcomes in women taking ethinylestradiol/drospirenone and other oral contraceptives (abstr 154). Pharmacoepidemiol Drug Saf 2006;15:S72
49. Koltun W, Lucky AW, Thiboutot D, et al: Efficacy and safety of 3 mg drospirenone/20 meg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception 2008;77:249-256
50. iPLEDGE. Available at: www.ipledgeprogram.com/Abouti-PLEDGE.aspx. Accessed July 2008
51. DiGiovanna JJ: Isotretinoin effects on bone. J Am Acad Dermatol 2001;45:S176-S182
52. Choi J, Kimball AB: Acne beliefs: Fact and fiction. Cosmetic Dermatol 2005;8:571-576
53. Archer JS, Archer DF: Oral contraceptive efficacy and antibiotic interaction: A myth debunked. J Am Acad Dermatol 2002;46:917-923
54. Gollnick H, Cunliffe W, Berson D, et al, and the Global Alliance to Improve Outcomes in Acne: Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol (suppl 1) 2003;49:S1-S37